1
|
Kontogiannis T, Braybrook J, McElroy C, Foy C, Whale AS, Quaglia M, Smales CM. Characterization of AAV vectors: A review of analytical techniques and critical quality attributes. Mol Ther Methods Clin Dev 2024; 32:101309. [PMID: 39234444 PMCID: PMC11372808 DOI: 10.1016/j.omtm.2024.101309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/06/2024]
Abstract
Standardized evaluation of adeno-associated virus (AAV) vector products for biotherapeutic application is essential to ensure the safety and efficacy of gene therapies. This includes analyzing the critical quality attributes of the product. However, many of the current analytical techniques used to assess these attributes have limitations, including low throughput, large sample requirements, poorly understood measurement variability, and lack of comparability between methods. To address these challenges, it is essential to establish higher-order reference methods that can be used for comparability measurements, optimization of current assays, and development of reference materials. Highly precise methods are necessary for measuring the empty/partial/full capsid ratios and the titer of AAV vectors. Additionally, it is important to develop methods for the measurement of less-established critical quality attributes, including post-translational modifications, capsid stoichiometry, and methylation profiles. By doing so, we can gain a better understanding of the influence of these attributes on the quality of the product. Moreover, quantification of impurities, such as host-cell proteins and DNA contaminants, is crucial for obtaining regulatory approval. The development and application of refined methodologies will be essential to thoroughly characterize AAV vectors by informing process development and facilitating the generation of reference materials for assay validation and calibration.
Collapse
Affiliation(s)
- Theodoros Kontogiannis
- School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, Kent CT2 7NJ, UK
- National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK
| | - Julian Braybrook
- National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK
| | | | - Carole Foy
- National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK
| | - Alexandra S Whale
- National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK
| | - Milena Quaglia
- Reading Scientific Services Ltd, Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading Berkshire RG6 6LA, UK
| | - C Mark Smales
- School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, Kent CT2 7NJ, UK
- National Institute for Bioprocessing Research and Training, Blackrock, Co, Foster Avenue, A94 X099 Mount Merrion, Dublin, Ireland
| |
Collapse
|
2
|
Limpikirati PK, Mongkoltipparat S, Denchaipradit T, Siwasophonpong N, Pornnopparat W, Ramanandana P, Pianpaktr P, Tongchusak S, Tian MT, Pisitkun T. Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics. J Pharm Anal 2024; 14:100916. [PMID: 39035218 PMCID: PMC11259812 DOI: 10.1016/j.jpha.2023.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/04/2023] [Accepted: 12/07/2023] [Indexed: 07/23/2024] Open
Abstract
In this review, we focus on providing basics and examples for each component of the protein therapeutic specifications to interested pharmacists and biopharmaceutical scientists with a goal to strengthen understanding in regulatory science and compliance. Pharmaceutical specifications comprise a list of important quality attributes for testing, references to use for test procedures, and appropriate acceptance criteria for the tests, and they are set up to ensure that when a drug product is administered to a patient, its intended therapeutic benefits and safety can be rendered appropriately. Conformance of drug substance or drug product to the specifications is achieved by testing an article according to the listed tests and analytical methods and obtaining test results that meet the acceptance criteria. Quality attributes are chosen to be tested based on their quality risk, and consideration should be given to the merit of the analytical methods which are associated with the acceptance criteria of the specifications. Acceptance criteria are set forth primarily based on efficacy and safety profiles, with an increasing attention noted for patient-centric specifications. Discussed in this work are related guidelines that support the biopharmaceutical specification setting, how to set the acceptance criteria, and examples of the quality attributes and the analytical methods from 60 articles and 23 pharmacopeial monographs. Outlooks are also explored on process analytical technologies and other orthogonal tools which are on-trend in biopharmaceutical characterization and quality control.
Collapse
Affiliation(s)
- Patanachai K. Limpikirati
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Pharmaceutical Sciences and Technology (PST) Graduate Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Sorrayut Mongkoltipparat
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Thinnaphat Denchaipradit
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Nathathai Siwasophonpong
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Wudthipong Pornnopparat
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Parawan Ramanandana
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Pharmaceutical Sciences and Technology (PST) Graduate Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Bang Phli, Samut Prakan, 10540, Thailand
| | - Phumrapee Pianpaktr
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Pharmaceutical Sciences and Technology (PST) Graduate Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Songsak Tongchusak
- Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Maoxin Tim Tian
- Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| | - Trairak Pisitkun
- Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
- Division of Research Affairs, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand
| |
Collapse
|
3
|
Mi W, Zhang X, Wang B, Sun R, Ma S, Hu Z, Dai X. Absolute protein quantification based on calibrated particle counting using electrospray-differential mobility analysis. Anal Chim Acta 2024; 1304:342534. [PMID: 38637035 DOI: 10.1016/j.aca.2024.342534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 03/13/2024] [Accepted: 03/25/2024] [Indexed: 04/20/2024]
Abstract
The traceability of in vitro diagnostics or drug products is based on the accurate quantification of proteins. In this study, we developed an absolute quantification approach for proteins. This method is based on calibrated particle counting using electrospray-differential mobility analysis (ES-DMA) coupled with a condensation particle counter (CPC). The absolute concentration of proteins was quantified with the observed protein particle number measured with ES-DMA-CPC, and the detection efficiency was determined by calibrators. The measurement performance and quantitative level were verified using two certificated reference materials, BSA and NIMCmAb. The linear regression fit for the detection efficiency values of three reference materials and one highly purified protein (myoglobin, BSA, NIMCmAb and fibrinogen) indicated that the detection efficiency and the particle size distribution of these proteins exhibited a linear relationship. Moreover, to explore the suitability of the detection efficiency-particle size curve for protein quantification, the concentrations of three typical proteinaceous particles, including two high molecular weight proteins (NIST reference material 8671 and D-dimer) and one protein complex (glutathione S-transferase dimer), were determined. This work suggests that this calibrated particle counting method is an efficient approach for nondestructive, rapid and accurate quantification of proteins, especially for measuring proteinaceous particles with tremendous size and without reference standards.
Collapse
Affiliation(s)
- Wei Mi
- National Institute of Metrology, No.18 Beisanhuan Donglu, Beijing, 100029, China.
| | - Xinyi Zhang
- National Institute of Metrology, No.18 Beisanhuan Donglu, Beijing, 100029, China
| | - Bin Wang
- National Institute of Metrology, No.18 Beisanhuan Donglu, Beijing, 100029, China
| | - Ruixue Sun
- College of Life Sciences, China Jiliang University, Xueyuan Street 258, Hangzhou, 310018, China
| | - Shangying Ma
- College of Life Sciences, China Jiliang University, Xueyuan Street 258, Hangzhou, 310018, China
| | - Zhishang Hu
- National Institute of Metrology, No.18 Beisanhuan Donglu, Beijing, 100029, China.
| | - Xinhua Dai
- National Institute of Metrology, No.18 Beisanhuan Donglu, Beijing, 100029, China.
| |
Collapse
|
4
|
Tank P, Vora S, Tripathi S, D'Souza F. Qualification of a LC-HRMS platform method for biosimilar development using NISTmab as a model. Anal Biochem 2024; 688:115475. [PMID: 38336012 DOI: 10.1016/j.ab.2024.115475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 12/27/2023] [Accepted: 01/26/2024] [Indexed: 02/12/2024]
Abstract
Biosimilars are a cost-effective alternative to biopharmaceuticals, necessitating rigorous analytical methods for consistency and compliance. Liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) is a versatile tool for assessing key attributes, encompassing molecular mass, primary structure, and post-translational modifications (PTMs). Adhering to ICH Q2R1, we validated an LC-HRMS based peptide mapping method using NISTmab as a reference. The method validation parameters, covering system suitability, specificity, accuracy, precision, robustness, and carryover, were comprehensively assessed. The method effectively differentiated the NISTmab from similar counterparts as well as from artificially introduced spiked conditions. Notably, the accuracy of mass error for NISTmab specific complementarity determining region peptides was within a maximum of 2.42 parts per million (ppm) from theoretical and the highest percent relative standard deviation (%RSD) observed for precision was 0.000219 %. It demonstrates precision in sequence coverage and PTM detection, with a visual inspection of total ion chromatogram approach for variability assessment. The method maintains robustness when subjected to diverse storage conditions, encompassing variations in column temperature and mobile phase composition. Negligible carryover was noted during the carryover analysis. In summary, this method serves as a versatile platform for multiple biosimilar development by effectively characterizing and identifying monoclonal antibodies, ultimately ensuring product quality.
Collapse
Affiliation(s)
- Paresh Tank
- Analytical Chemistry Division of Zelle Biotechnology Research and Analytical Services, Zelle Biotechnology Pvt. Ltd., A-7 M.I.D.C., Mira Industrial Area, Western Express Highway, Mira Road, Thane, 401 104, India.
| | - Shruti Vora
- Analytical Chemistry Division of Zelle Biotechnology Research and Analytical Services, Zelle Biotechnology Pvt. Ltd., A-7 M.I.D.C., Mira Industrial Area, Western Express Highway, Mira Road, Thane, 401 104, India.
| | - Sarita Tripathi
- Analytical Chemistry Division of Zelle Biotechnology Research and Analytical Services, Zelle Biotechnology Pvt. Ltd., A-7 M.I.D.C., Mira Industrial Area, Western Express Highway, Mira Road, Thane, 401 104, India.
| | - Fatima D'Souza
- Analytical Chemistry Division of Zelle Biotechnology Research and Analytical Services, Zelle Biotechnology Pvt. Ltd., A-7 M.I.D.C., Mira Industrial Area, Western Express Highway, Mira Road, Thane, 401 104, India.
| |
Collapse
|
5
|
Ju DU, Park D, Kim IH, Kim S, Yoo HM. Development of Human Rhinovirus RNA Reference Material Using Digital PCR. Genes (Basel) 2023; 14:2210. [PMID: 38137032 PMCID: PMC10742479 DOI: 10.3390/genes14122210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/08/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023] Open
Abstract
The human rhinovirus (RV) is a positive-stranded RNA virus that causes respiratory tract diseases affecting both the upper and lower halves of the respiratory system. RV enhances its replication by concentrating RNA synthesis within a modified host membrane in an intracellular compartment. RV infections often occur alongside infections caused by other respiratory viruses, and the RV virus may remain asymptomatic for extended periods. Alongside qualitative detection, it is essential to accurately quantify RV RNA from clinical samples to explore the relationships between RV viral load, infections caused by the virus, and the resulting symptoms observed in patients. A reference material (RM) is required for quality evaluation, the performance evaluation of molecular diagnostic products, and evaluation of antiviral agents in the laboratory. The preparation process for the RM involves creating an RV RNA mixture by combining RV viral RNA with RNA storage solution and matrix. The resulting RV RNA mixture is scaled up to a volume of 25 mL, then dispensed at 100 µL per vial and stored at -80 °C. The process of measuring the stability and homogeneity of RV RMs was conducted by employing reverse transcription droplet digital polymerase chain reaction (RT-ddPCR). Digital PCR is useful for the analysis of standards and can help to improve measurement compatibility: it represents the equivalence of a series of outcomes for reference materials and samples being analyzed when a few measurement procedures are employed, enabling objective comparisons between quantitative findings obtained through various experiments. The number of copies value represents a measured result of approximately 1.6 × 105 copies/μL. The RM has about an 11% bottle-to-bottle homogeneity and shows stable results for 1 week at temperatures of 4 °C and -20 °C and for 12 months at a temperature of -80 °C. The developed RM can enhance the dependability of RV molecular tests by providing a precise reference value for the absolute copy number of a viral target gene. Additionally, it can serve as a reference for diverse studies.
Collapse
Affiliation(s)
- Dong U Ju
- Biometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
- School of Biomedical Engineering, Korea University, Seoul 02841, Republic of Korea
| | - Dongju Park
- Biometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Il-Hwan Kim
- Biometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Seil Kim
- Biometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
- Department of Precision Measurement, University of Science & Technology (UST), Daejeon 34113, Republic of Korea
| | - Hee Min Yoo
- Biometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
- Department of Precision Measurement, University of Science & Technology (UST), Daejeon 34113, Republic of Korea
| |
Collapse
|
6
|
Solomon TL, Chao K, Gingras G, Aubin Y, O'Dell WB, Marino JP, Brinson RG. Backbone NMR assignment of the yeast expressed Fab fragment of the NISTmAb reference antibody. BIOMOLECULAR NMR ASSIGNMENTS 2023; 17:75-81. [PMID: 36856943 DOI: 10.1007/s12104-023-10123-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Accepted: 02/08/2023] [Indexed: 06/02/2023]
Abstract
The monoclonal antibody (mAb) protein class has become a primary therapeutic platform for the production of new life saving drug products. MAbs are comprised of two domains: the antigen-binding fragment (Fab) and crystallizable fragment (Fc). Despite the success in the clinic, NMR assignments of the complete Fab domain have been elusive, in part due to problems in production of properly folded, triply-labeled 2H,13C,15N Fab domain. Here, we report the successful recombinant expression of a triply-labeled Fab domain, derived from the standard IgG1κ known as NISTmAb, in yeast. Using the 2H,13C,15N Fab domain, we assigned 94% of the 1H, 13C, and 15N backbone atoms.
Collapse
Affiliation(s)
- Tsega L Solomon
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA
| | - Kinlin Chao
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA
| | - Genevieve Gingras
- Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiotherapeutic Drugs Directorate, Health Canada, 251 Sir Frederick Banting Driveway, K1A 0K9, Ottawa, ON, Canada
| | - Yves Aubin
- Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiotherapeutic Drugs Directorate, Health Canada, 251 Sir Frederick Banting Driveway, K1A 0K9, Ottawa, ON, Canada
| | - William B O'Dell
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA
| | - John P Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA
| | - Robert G Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA.
| |
Collapse
|
7
|
Solomon TL, Delaglio F, Giddens JP, Marino JP, Yu YB, Taraban MB, Brinson RG. Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb. MAbs 2023; 15:2160227. [PMID: 36683157 PMCID: PMC9872951 DOI: 10.1080/19420862.2022.2160227] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
The clinical efficacy and safety of protein-based drugs such as monoclonal antibodies (mAbs) rely on the integrity of the protein higher order structure (HOS) during product development, manufacturing, storage, and patient administration. As mAb-based drugs are becoming more prevalent in the treatment of many illnesses, the need to establish metrics for quality attributes of mAb therapeutics through high-resolution techniques is also becoming evident. To this end, here we used a forced degradation method, time-dependent oxidation by hydrogen peroxide, on the model biotherapeutic NISTmAb and evaluated the effects on HOS with orthogonal analytical methods and a functional assay. To monitor the oxidation process, the experimental workflow involved incubation of NISTmAb with hydrogen peroxide in a benchtop nuclear magnetic resonance spectrometer (NMR) that followed the reaction kinetics, in real-time through the water proton transverse relaxation rate R2(1H2O). Aliquots taken at defined time points were further analyzed by high-field 2D 1H-13C methyl correlation fingerprint spectra in parallel with other analytical techniques, including thermal unfolding, size-exclusion chromatography, and surface plasmon resonance, to assess changes in stability, heterogeneity, and binding affinities. The complementary measurement outputs from the different techniques demonstrate the utility of combining NMR with other analytical tools to monitor oxidation kinetics and extract the resulting structural changes in mAbs that are functionally relevant, allowing rigorous assessment of HOS attributes relevant to the efficacy and safety of mAb-based drug products.
Collapse
Affiliation(s)
- Tsega L. Solomon
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, Maryland, United States
| | - Frank Delaglio
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, Maryland, United States
| | - John P. Giddens
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, Maryland, United States
| | - John P. Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, Maryland, United States
| | - Yihua Bruce Yu
- Bio- and Nano-Technology Center, University of Maryland School of Pharmacy, and Institute for Bioscience and Biotechnology Research, Rockville, Maryland, United States
| | - Marc B. Taraban
- Bio- and Nano-Technology Center, University of Maryland School of Pharmacy, and Institute for Bioscience and Biotechnology Research, Rockville, Maryland, United States
| | - Robert G. Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, Maryland, United States,CONTACT Robert G. Brinson Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, 9600 Gudelsky Drive Rockville, Rockville, Maryland20850, United States
| |
Collapse
|
8
|
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Niu B, Wang J, Xu W, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H. Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2022; 33:1659-1677. [PMID: 36018776 PMCID: PMC9460773 DOI: 10.1021/jasms.2c00129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 08/01/2022] [Accepted: 08/02/2022] [Indexed: 05/23/2023]
Abstract
The multi-attribute method (MAM) was conceived as a single assay to potentially replace multiple single-attribute assays that have long been used in process development and quality control (QC) for protein therapeutics. MAM is rooted in traditional peptide mapping methods; it leverages mass spectrometry (MS) detection for confident identification and quantitation of many types of protein attributes that may be targeted for monitoring. While MAM has been widely explored across the industry, it has yet to gain a strong foothold within QC laboratories as a replacement method for established orthogonal platforms. Members of the MAM consortium recently undertook an interlaboratory study to evaluate the industry-wide status of MAM. Here we present the results of this study as they pertain to the targeted attribute analytics component of MAM, including investigation into the sources of variability between laboratories and comparison of MAM data to orthogonal methods. These results are made available with an eye toward aiding the community in further optimizing the method to enable its more frequent use in the QC environment.
Collapse
Affiliation(s)
- Trina Mouchahoir
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - John E. Schiel
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - Rich Rogers
- Just-Evotech
Biologics, Inc., 401
Terry Ave N., Seattle, Washington 98109, United States
| | - Alan Heckert
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
| | - Benjamin J. Place
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
| | - Aaron Ammerman
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Xiaoxiao Li
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Tom Robinson
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Brian Schmidt
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Chris M. Chumsae
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Xinbi Li
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Anton V. Manuilov
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Bo Yan
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Gregory O. Staples
- Agilent
Technologies, 5301 Stevens Creek Blvd, Santa Clara, California 95008, United States
| | - Da Ren
- Amgen, One Amgen Center Dr, Thousand
Oaks, California 91320, United States
| | - Alexander J. Veach
- Amgen, One Amgen Center Dr, Thousand
Oaks, California 91320, United States
| | - Dongdong Wang
- BioAnalytix, 790 Memorial Dr, Cambridge, Massachusetts 02139, United States
| | - Wael Yared
- BioAnalytix, 790 Memorial Dr, Cambridge, Massachusetts 02139, United States
| | - Zoran Sosic
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Yan Wang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Li Zang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Anthony M. Leone
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Peiran Liu
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Richard Ludwig
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Li Tao
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Wei Wu
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Ahmet Cansizoglu
- Charles
River Laboratories, 8
Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Andrew Hanneman
- Charles
River Laboratories, 8
Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Greg W. Adams
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Irina Perdivara
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Hunter Walker
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Margo Wilson
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | | | - Nick DeGraan-Weber
- Genedata, 750 Marrett Road, One Cranberry
Hill, Lexington, Massachusetts 02421, United States
| | - Stefano Gotta
- Genedata, Margarethenstrasse 38, Basel, 4053, Switzerland
| | - Joe Shambaugh
- Genedata, 750 Marrett Road, One Cranberry
Hill, Lexington, Massachusetts 02421, United States
| | - Melissa Alvarez
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - X. Christopher Yu
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Li Cao
- GSK, 709
Swedeland Rd, King of Prussia, Pennsylvania 19406, United States
| | - Chun Shao
- GSK, 709
Swedeland Rd, King of Prussia, Pennsylvania 19406, United States
| | - Andrew Mahan
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Hirsh Nanda
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Kristen Nields
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Nancy Nightlinger
- Just-Evotech
Biologics, Inc., 401
Terry Ave N., Seattle, Washington 98109, United States
| | - Ben Niu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Jihong Wang
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Wei Xu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Gabriella Leo
- EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma), 00012, Italy
| | - Nunzio Sepe
- EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma), 00012, Italy
| | - Yan-Hui Liu
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Bhumit A. Patel
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Douglas Richardson
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Yi Wang
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Daniela Tizabi
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - Oleg V. Borisov
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Yali Lu
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Ernest L. Maynard
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | | | | | | | | | - Simon Letarte
- Pfizer, 375 N Field Dr, Lake Forest, Illinois 60045, United
States
| | - Sean Shen
- Pfizer, 375 N Field Dr, Lake Forest, Illinois 60045, United
States
| | - Kristin Boggio
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Keith Johnson
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Wenqin Ni
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Himakshi Patel
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - David Ripley
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Jason C. Rouse
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Ying Zhang
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Carly Daniels
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Andrew Dawdy
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Olga Friese
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Thomas W. Powers
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Justin B. Sperry
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Josh Woods
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Eric Carlson
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - K. Ilker Sen
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - St John Skilton
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - Michelle Busch
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Anders Lund
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Martha Stapels
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Xu Guo
- SCIEX, 71 Four Valley Drive, Concord, ON L4K
4V8, Canada
| | | | | | - Sean McCarthy
- SCIEX, 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States
| | - John Kim
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Jing Zhen
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Ying Zhou
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Sarah Rogstad
- U.S. Food
and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Xiaoshi Wang
- U.S. Food
and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Jing Fang
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | - Weibin Chen
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | - Ying Qing Yu
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | | | - Rebecca Scott
- Zoetis, 333 Portage St, Kalamazoo, Michigan 49007, United
States
| | - Hua Yuan
- Zoetis, 333 Portage St, Kalamazoo, Michigan 49007, United
States
| |
Collapse
|
9
|
Yandrofski K, Mouchahoir T, De Leoz ML, Duewer D, Hudgens JW, Anderson KW, Arbogast L, Delaglio F, Brinson RG, Marino JP, Phinney K, Tarlov M, Schiel JE. Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics. Front Mol Biosci 2022; 9:876780. [PMID: 35601836 PMCID: PMC9117750 DOI: 10.3389/fmolb.2022.876780] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 03/21/2022] [Indexed: 01/18/2023] Open
Abstract
Biopharmaceuticals such as monoclonal antibodies are required to be rigorously characterized using a wide range of analytical methods. Various material properties must be characterized and well controlled to assure that clinically relevant features and critical quality attributes are maintained. A thorough understanding of analytical method performance metrics, particularly emerging methods designed to address measurement gaps, is required to assure methods are appropriate for their intended use in assuring drug safety, stability, and functional activity. To this end, a series of interlaboratory studies have been conducted using NISTmAb, a biopharmaceutical-representative and publicly available monoclonal antibody test material, to report on state-of-the-art method performance, harmonize best practices, and inform on potential gaps in the analytical measurement infrastructure. Reported here is a summary of the study designs, results, and future perspectives revealed from these interlaboratory studies which focused on primary structure, post-translational modifications, and higher order structure measurements currently employed during biopharmaceutical development.
Collapse
Affiliation(s)
- Katharina Yandrofski
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
- *Correspondence: Katharina Yandrofski,
| | - Trina Mouchahoir
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | | | - David Duewer
- National Institute of Standards and Technology, Gaithersburg, MD, United States
| | - Jeffrey W. Hudgens
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Kyle W. Anderson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Luke Arbogast
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Frank Delaglio
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Robert G. Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - John P. Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Karen Phinney
- National Institute of Standards and Technology, Gaithersburg, MD, United States
| | - Michael Tarlov
- National Institute of Standards and Technology, Gaithersburg, MD, United States
| | - John E. Schiel
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| |
Collapse
|
10
|
MALDI-TOF-MS-Based Identification of Monoclonal Murine Anti-SARS-CoV-2 Antibodies within One Hour. Antibodies (Basel) 2022; 11:antib11020027. [PMID: 35466280 PMCID: PMC9036215 DOI: 10.3390/antib11020027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 04/05/2022] [Accepted: 04/07/2022] [Indexed: 02/06/2023] Open
Abstract
During the SARS-CoV-2 pandemic, many virus-binding monoclonal antibodies have been developed for clinical and diagnostic purposes. This underlines the importance of antibodies as universal bioanalytical reagents. However, little attention is given to the reproducibility crisis that scientific studies are still facing to date. In a recent study, not even half of all research antibodies mentioned in publications could be identified at all. This should spark more efforts in the search for practical solutions for the traceability of antibodies. For this purpose, we used 35 monoclonal antibodies against SARS-CoV-2 to demonstrate how sequence-independent antibody identification can be achieved by simple means applied to the protein. First, we examined the intact and light chain masses of the antibodies relative to the reference material NIST-mAb 8671. Already half of the antibodies could be identified based solely on these two parameters. In addition, we developed two complementary peptide mass fingerprinting methods with MALDI-TOF-MS that can be performed in 60 min and had a combined sequence coverage of over 80%. One method is based on the partial acidic hydrolysis of the protein by 5 mM of sulfuric acid at 99 °C. Furthermore, we established a fast way for a tryptic digest without an alkylation step. We were able to show that the distinction of clones is possible simply by a brief visual comparison of the mass spectra. In this work, two clones originating from the same immunization gave the same fingerprints. Later, a hybridoma sequencing confirmed the sequence identity of these sister clones. In order to automate the spectral comparison for larger libraries of antibodies, we developed the online software ABID 2.0. This open-source software determines the number of matching peptides in the fingerprint spectra. We propose that publications and other documents critically relying on monoclonal antibodies with unknown amino acid sequences should include at least one antibody fingerprint. By fingerprinting an antibody in question, its identity can be confirmed by comparison with a library spectrum at any time and context.
Collapse
|
11
|
Bou-Assaf GM, Budyak IL, Brenowitz M, Day ES, Hayes D, Hill J, Majumdar R, Ringhieri P, Schuck P, Lin JC. Best Practices for Aggregate Quantitation of Antibody Therapeutics by Sedimentation Velocity Analytical Ultracentrifugation. J Pharm Sci 2022; 111:2121-2133. [PMID: 34986360 DOI: 10.1016/j.xphs.2021.12.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Revised: 12/24/2021] [Accepted: 12/24/2021] [Indexed: 11/18/2022]
Abstract
Analytical ultracentrifugation (AUC) is a critical analytical tool supporting the development and manufacture of protein therapeutics. AUC is routinely used as an assay orthogonal to size exclusion chromatography for aggregate quantitation. This article distills the experimental and analysis procedures used by the authors for sedimentation velocity AUC into a series of best-practices considerations. The goal of this distillation is to help harmonize aggregate quantitation approaches across the biopharmaceutical industry. We review key considerations for sample and instrument suitability, experimental design, and data analysis best practices and conversely, highlight potential pitfalls to accurate aggregate analysis. Our goal is to provide experienced users benchmarks against which they can standardize their analyses and to provide guidance for new AUC analysts that will aid them to become proficient in this fundamental technique.
Collapse
Affiliation(s)
| | - Ivan L Budyak
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
| | - Michael Brenowitz
- Departments of Biochemistry and Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461
| | - Eric S Day
- Pharmaceutical Development, Genentech a Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080
| | - David Hayes
- IntlSoSci, 23 Washington St., Gorham, NH 03581
| | - John Hill
- Department of Bioengineering, University of Washington, Seattle, WA 98105
| | - Ranajoy Majumdar
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
| | - Paola Ringhieri
- Analytical Development Biotech Department, Merck Serono S.p.a, Guidonia, RM, Italy; an affiliate of Merck KGaA
| | - Peter Schuck
- Laboratory of Dynamics of Macromolecular Assembly, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 13 South Drive, Bethesda, MD 20892
| | - Jasper C Lin
- Pharmaceutical Development, Genentech a Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080.
| |
Collapse
|
12
|
Capillary electrophoresis and the biopharmaceutical industry: Therapeutic protein analysis and characterization. Trends Analyt Chem 2021. [DOI: 10.1016/j.trac.2021.116407] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
13
|
Site-specific glycan-conjugated NISTmAb antibody drug conjugate mimetics: synthesis, characterization, and utility. Anal Bioanal Chem 2021; 413:4989-5001. [PMID: 34231000 DOI: 10.1007/s00216-021-03460-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 06/01/2021] [Accepted: 06/08/2021] [Indexed: 10/20/2022]
Abstract
Antibody drug conjugates (ADCs) represent a rapidly growing modality for the treatment of numerous oncology indications. The complexity of analytical characterization method development is increased due to the potential for synthetic intermediates and process-related impurities. In addition, the cytotoxicity of such materials provides an additional challenge with regard to handling products and/or sharing materials with analytical collaborators and/or vendors for technology development. Herein, we have utilized a site-specific chemoenzymatic glycoconjugation strategy for preparing ADC mimetics composed of the NIST monoclonal antibody (NISTmAb) conjugated to non-cytotoxic payloads representing both small molecules and peptides. The materials were exhaustively characterized with high-resolution mass spectrometry-based approaches to demonstrate the utility of each analytical method for confirming the conjugation fidelity as well as deep characterization of low-abundance synthetic intermediates and impurities arising from payload raw material heterogeneity. These materials therefore represent a widely available test metric to develop novel ADC analytical methods as well as a platform to discuss best practices for extensive characterization.
Collapse
|
14
|
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Barysz HM, Jahn M, Niu B, Wang J, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H. New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:913-928. [PMID: 33710905 DOI: 10.1021/jasms.0c00415] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
The Multi-Attribute Method (MAM) Consortium was initially formed as a venue to harmonize best practices, share experiences, and generate innovative methodologies to facilitate widespread integration of the MAM platform, which is an emerging ultra-high-performance liquid chromatography-mass spectrometry application. Successful implementation of MAM as a purity-indicating assay requires new peak detection (NPD) of potential process- and/or product-related impurities. The NPD interlaboratory study described herein was carried out by the MAM Consortium to report on the industry-wide performance of NPD using predigested samples of the NISTmAb Reference Material 8671. Results from 28 participating laboratories show that the NPD parameters being utilized across the industry are representative of high-resolution MS performance capabilities. Certain elements of NPD, including common sources of variability in the number of new peaks detected, that are critical to the performance of the purity function of MAM were identified in this study and are reported here as a means to further refine the methodology and accelerate adoption into manufacturer-specific protein therapeutic product life cycles.
Collapse
Affiliation(s)
- Trina Mouchahoir
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - John E Schiel
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - Rich Rogers
- Just - Evotech Biologics, 401 Terry Avenue N, Seattle, Washington 98109, United States
| | - Alan Heckert
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Benjamin J Place
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Aaron Ammerman
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Xiaoxiao Li
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Tom Robinson
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Brian Schmidt
- AbbVie, 1500 Seaport Boulevard, Redwood City, California 94063, United States
| | - Chris M Chumsae
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Xinbi Li
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Anton V Manuilov
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Bo Yan
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Gregory O Staples
- Agilent Technologies, 5301 Stevens Creek Boulevard, Santa Clara, California 95008, United States
| | - Da Ren
- Amgen, One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alexander J Veach
- Amgen, One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dongdong Wang
- BioAnalytix, 790 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Wael Yared
- BioAnalytix, 790 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Zoran Sosic
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Yan Wang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Li Zang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Anthony M Leone
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Peiran Liu
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Richard Ludwig
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Li Tao
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Wei Wu
- Bristol-Myers Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Ahmet Cansizoglu
- Charles River Laboratories, 8 Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Andrew Hanneman
- Charles River Laboratories, 8 Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Greg W Adams
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | - Irina Perdivara
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | - Hunter Walker
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | - Margo Wilson
- FUJIFILM Diosynth Biotechnologies, 101 J. Morris Commons Lane, Morrisville, North Carolina 27560, United States
| | | | - Nick DeGraan-Weber
- Genedata, 750 Marrett Road, One Cranberry Hill, Lexington, Massachusetts 02421, United States
| | - Stefano Gotta
- Genedata, Margarethenstrasse 38, Basel 4053, Switzerland
| | - Joe Shambaugh
- Genedata, 750 Marrett Road, One Cranberry Hill, Lexington, Massachusetts 02421, United States
| | - Melissa Alvarez
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - X Christopher Yu
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Li Cao
- GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Chun Shao
- GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Andrew Mahan
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Hirsh Nanda
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Kristen Nields
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Nancy Nightlinger
- Just - Evotech Biologics, 401 Terry Avenue N, Seattle, Washington 98109, United States
| | | | - Michael Jahn
- Lonza, Hochbergerstrasse 60 A, Basel 4057, Switzerland
| | - Ben Niu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Jihong Wang
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Gabriella Leo
- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma) 00012, Italy
| | - Nunzio Sepe
- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma) 00012, Italy
| | - Yan-Hui Liu
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Bhumit A Patel
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Douglas Richardson
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Yi Wang
- Merck & Co., Inc., 2000 Galloping Hill Roa, Kenilworth, New Jersey 07033, United States
| | - Daniela Tizabi
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - Oleg V Borisov
- Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Yali Lu
- Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Ernest L Maynard
- Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | | | | | | | | | - Simon Letarte
- Pfizer, 375 North Field Drive, Lake Forest, Illinois 60045, United States
| | - Sean Shen
- Pfizer, 375 North Field Drive, Lake Forest, Illinois 60045, United States
| | - Kristin Boggio
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Keith Johnson
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Wenqin Ni
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Himakshi Patel
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - David Ripley
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Jason C Rouse
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Ying Zhang
- Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States
| | - Carly Daniels
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Andrew Dawdy
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Olga Friese
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Thomas W Powers
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Justin B Sperry
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Josh Woods
- Pfizer, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Eric Carlson
- Protein Metrics, Inc., 20863 Stevens Creek Boulevard, Cupertino, California 95014, United States
| | - K Ilker Sen
- Protein Metrics, Inc., 20863 Stevens Creek Boulevard, Cupertino, California 95014, United States
| | - St John Skilton
- Protein Metrics, Inc., 20863 Stevens Creek Boulevard, Cupertino, California 95014, United States
| | - Michelle Busch
- Sanofi, 1 The Mountain Road, Framingham, Massachusetts 01701, United States
| | - Anders Lund
- Sanofi, 1 The Mountain Road, Framingham, Massachusetts 01701, United States
| | - Martha Stapels
- Sanofi, 1 The Mountain Road, Framingham, Massachusetts 01701, United States
| | - Xu Guo
- SCIEX, 71 Four Valley Drive, Concord, ON L4K 4 V8, Canada
| | | | | | - Sean McCarthy
- SCIEX, 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States
| | - John Kim
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Jing Zhen
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Ying Zhou
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Sarah Rogstad
- U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Xiaoshi Wang
- U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Jing Fang
- Waters, 34 Maple Street, Milford, Massachusetts 01757, United States
| | - Weibin Chen
- Waters, 34 Maple Street, Milford, Massachusetts 01757, United States
| | - Ying Qing Yu
- Waters, 34 Maple Street, Milford, Massachusetts 01757, United States
| | | | - Rebecca Scott
- Zoetis, 333 Portage Street, Kalamazoo, Michigan 49007, United States
| | - Hua Yuan
- Zoetis, 333 Portage Street, Kalamazoo, Michigan 49007, United States
| |
Collapse
|
15
|
Rincon Pabon JP, Kochert BA, Liu YH, Richardson DD, Weis DD. Protein A does not induce allosteric structural changes in an IgG1 antibody during binding. J Pharm Sci 2021; 110:2355-2361. [PMID: 33640336 DOI: 10.1016/j.xphs.2021.02.027] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 02/22/2021] [Accepted: 02/23/2021] [Indexed: 10/22/2022]
Abstract
Affinity chromatography is widely used for antibody purification in biopharmaceutical production. Although there is evidence suggesting that affinity chromatography might induce structural changes in antibodies, allosteric changes in structure have not been well-explored. Here, we used hydrogen exchange-mass spectrometry (HX-MS) to reveal conformational changes in the NIST mAb upon binding with a protein A (ProA) matrix. HX-MS measurements of NIST mAb bound to in-solution and resin forms of ProA revealed regions of the CH2 and CH3 domains with increased protection from HX upon ProA binding, consistent with the known ProA binding region. In-solution ProA experiments revealed regions in the Fab with increased HX uptake when the ProA:mAb molar ratio was increased to 2:1, suggesting an allosterically induced increase in backbone flexibility. Such effects were not observed with lower ProA concentration (1:1 molar ratio) or when ProA resin was used, suggesting some kind of change in binding mode. Since all pharmaceutical processes use ProA bound to resin, our results rule out reversible allosteric effects on the NIST mAb during interaction with resin ProA. However, irreversible effects cannot be ruled out since the NIST mAb was previously exposed to ProA during its original purification.
Collapse
Affiliation(s)
- Juan P Rincon Pabon
- Department of Chemistry and the Ralph N. Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, United States
| | - Brent A Kochert
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Yan-Hui Liu
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Douglas D Richardson
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, NJ, USA
| | - David D Weis
- Department of Chemistry and the Ralph N. Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, United States.
| |
Collapse
|
16
|
Lehman SE, Karageorgos I, Filteau JR, Vreeland WN. Effect of Azide Preservative on Thermomechanical Aggregation of Purified Reference Protein Materials. J Pharm Sci 2021; 110:1948-1957. [PMID: 33453208 DOI: 10.1016/j.xphs.2021.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 01/05/2021] [Accepted: 01/06/2021] [Indexed: 10/22/2022]
Abstract
Protein aggregation can affect the quality of protein-based therapeutics. Attempting to unravel factors influencing protein aggregation involves systematic studies. These studies often include sodium azide or similar preservatives in the aggregation buffer. This work shows effects of azide on aggregation of two highly purified reference proteins, both a bovine serum albumin (BSA) as well as a monoclonal antibody (NISTmAb). The proteins were aggregated by thermomechanical stress, consisting of simultaneous heating of the solution with gentle agitation. Protein aggregates were characterized by asymmetric flow field flow fractionation (AF4) with light scattering measurements along with quantification by UV spectroscopy, revealing strong time-dependent generation of aggregated protein and an increase in aggregate molar mass. Gel electrophoresis was used to probe the reversibility of the aggregation and demonstrated complete reversibility for the NISTmAb, but not so for the BSA. Kinetic fitting to a commonly implemented nucleated polymerization model was also employed to provide mechanistic details into the kinetic process. The model suggests that the aggregation of the NISTmAb proceeds via nucleated growth and aggregate-aggregate condensation in a way that is dependent on the concentration (and presence) of the azide anion. This work overall implicates azide preservatives as having demonstrable effects on thermomechanical stress and aggregation of proteins undergoing systematic aggregation and stability studies.
Collapse
Affiliation(s)
- Sean E Lehman
- Biomolecular Measurement Division, Bioprocess Measurements Group, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
| | - Ioannis Karageorgos
- Biomolecular Measurement Division, Bioprocess Measurements Group, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
| | - Jeremy R Filteau
- Biomolecular Measurement Division, Bioprocess Measurements Group, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA; Department of Chemical Engineering, University of Washington, Seattle, WA 98195, USA
| | - Wyatt N Vreeland
- Biomolecular Measurement Division, Bioprocess Measurements Group, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
| |
Collapse
|
17
|
Brinson RG, Elliott KW, Arbogast LW, Sheen DA, Giddens JP, Marino JP, Delaglio F. Principal component analysis for automated classification of 2D spectra and interferograms of protein therapeutics: influence of noise, reconstruction details, and data preparation. JOURNAL OF BIOMOLECULAR NMR 2020; 74:643-656. [PMID: 32700053 DOI: 10.1007/s10858-020-00332-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Accepted: 07/02/2020] [Indexed: 06/11/2023]
Abstract
Protein therapeutics have numerous critical quality attributes (CQA) that must be evaluated to ensure safety and efficacy, including the requirement to adopt and retain the correct three-dimensional fold without forming unintended aggregates. Therefore, the ability to monitor protein higher order structure (HOS) can be valuable throughout the lifecycle of a protein therapeutic, from development to manufacture. 2D NMR has been introduced as a robust and precise tool to assess the HOS of a protein biotherapeutic. A common use case is to decide whether two groups of spectra are substantially different, as an indicator of difference in HOS. We demonstrate a quantitative use of principal component analysis (PCA) scores to perform this decision-making, and demonstrate the effect of acquisition and processing details on class separation using samples of NISTmAb monoclonal antibody Reference Material subjected to two different oxidative stress protocols. The work introduces an approach to computing similarity from PCA scores based upon the technique of histogram intersection, a method originally developed for retrieval of images from large databases. Results show that class separation can be robust with respect to random noise, reconstruction method, and analysis region selection. By contrast, details such as baseline distortion can have a pronounced effect, and so must be controlled carefully. Since the classification approach can be performed without the need to identify peaks, results suggest that it is possible to use even more efficient measurement strategies that do not produce spectra that can be analyzed visually, but nevertheless allow useful decision-making that is objective and automated.
Collapse
Affiliation(s)
- Robert G Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD, 20850, USA
| | - K Wade Elliott
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD, 20850, USA
| | - Luke W Arbogast
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD, 20850, USA
| | - David A Sheen
- Chemical Sciences Division, National Institute of Standards and Technology, Gaithersburg, MD, 20899, USA
| | - John P Giddens
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD, 20850, USA
| | - John P Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD, 20850, USA
| | - Frank Delaglio
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD, 20850, USA.
| |
Collapse
|
18
|
Coffman J, Marques B, Orozco R, Aswath M, Mohammad H, Zimmermann E, Khouri J, Griesbach J, Izadi S, Williams A, Sankar K, Walters B, Lin J, Hepbildikler S, Schiel J, Welsh J, Ferreira G, Delmar J, Mody N, Afdahl C, Cui T, Khalaf R, Hanke A, Pampel L, Parimal S, Hong X, Patil U, Pollard J, Insaidoo F, Robinson J, Chandra D, Blanco M, Panchal J, Soundararajan S, Roush D, Tugcu N, Cramer S, Haynes C, Willson RC. Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences. Biotechnol Bioeng 2020; 117:2100-2115. [PMID: 32255523 DOI: 10.1002/bit.27349] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 03/05/2020] [Accepted: 04/04/2020] [Indexed: 01/08/2023]
Abstract
Biopharmaceutical product and process development do not yet take advantage of predictive computational modeling to nearly the degree seen in industries based on smaller molecules. To assess and advance progress in this area, spirited coopetition (mutually beneficial collaboration between competitors) was successfully used to motivate industrial scientists to develop, share, and compare data and methods which would normally have remained confidential. The first "Highland Games" competition was held in conjunction with the October 2018 Recovery of Biological Products Conference in Ashville, NC, with the goal of benchmarking and assessment of the ability to predict development-related properties of six antibodies from their amino acid sequences alone. Predictions included purification-influencing properties such as isoelectric point and protein A elution pH, and biophysical properties such as stability and viscosity at very high concentrations. Essential contributions were made by a large variety of individuals, including companies which consented to provide antibody amino acid sequences and test materials, volunteers who undertook the preparation and experimental characterization of these materials, and prediction teams who attempted to predict antibody properties from sequence alone. Best practices were identified and shared, and areas in which the community excels at making predictions were identified, as well as areas presenting opportunities for considerable improvement. Predictions of isoelectric point and protein A elution pH were especially good with all-prediction average errors of 0.2 and 1.6 pH unit, respectively, while predictions of some other properties were notably less good. This manuscript presents the events, methods, and results of the competition, and can serve as a tutorial and as a reference for in-house benchmarking by others. Organizations vary in their policies concerning disclosure of methods, but most managements were very cooperative with the Highland Games exercise, and considerable insight into common and best practices is available from the contributed methods. The accumulated data set will serve as a benchmarking tool for further development of in silico prediction tools.
Collapse
Affiliation(s)
| | - Bruno Marques
- Process Development, Century Therapeutics, Philadelphia, Pennsylvania
| | | | | | - Hasan Mohammad
- ProUnlimited supporting Boehringer Ingelheim Fremont Inc., Fremont, California
| | | | - Joelle Khouri
- ProUnlimited supporting Boehringer Ingelheim Fremont Inc., Fremont, California
| | | | - Saeed Izadi
- Genentech Inc., South San Francisco, California
| | | | | | | | - Jasper Lin
- Genentech Inc., South San Francisco, California
| | | | - John Schiel
- Institute of Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, Maryland
| | - John Welsh
- Pall Life Sciences, Portsmouth, UK.,Department of Biology and Biochemistry, University of Houston, Houston, Texas
| | | | | | | | | | | | | | | | | | - Siddharth Parimal
- Downstream Process Development, GlaxoSmithKline, King of Prussia, Pennsylvania
| | - Xuan Hong
- Protein Design and Informatics, GlaxoSmithKline, Collegeville, Pennsylvania
| | - Ujwal Patil
- Department of Biology and Biochemistry, University of Houston, Houston, Texas
| | - Jennifer Pollard
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | - Francis Insaidoo
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | - Julie Robinson
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | - Divya Chandra
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | - Marco Blanco
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | - Jainik Panchal
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | | | - David Roush
- BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey
| | - Nihal Tugcu
- Purification Process Development, Sanofi-aventis, Cambridge, Massachusetts
| | - Steven Cramer
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York
| | - Charles Haynes
- Department of Chemical and Biological Engineering, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Richard C Willson
- Protein Design and Informatics, GlaxoSmithKline, Collegeville, Pennsylvania.,Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas.,Escuela de Medicina y Ciencias de la Salud ITESM, Monterrey, Mexico
| |
Collapse
|
19
|
Atouf F, Venema J. Do Standards Matter? What is Their Value? J Pharm Sci 2020; 109:2387-2392. [PMID: 32360406 DOI: 10.1016/j.xphs.2020.04.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 04/09/2020] [Accepted: 04/23/2020] [Indexed: 12/12/2022]
Abstract
Standards allow us to manage expectations for a diverse range of goods and services across the globe. From coordinating international global telecommunications across 24 different time zones to ensuring access to safe drinking water, standards allow us to work, communicate, collaborate, and live with certain expectations about safety and efficacy. When standards are fit-for-purpose, they raise the quality of products and services without requiring us to think about how that quality is assured. The result is that the successful implementation of standards for certain products can counterintuitively make it easy to overlook their importance when creating policies and regulations for next-generation products, such as generic drugs vis-à-vis biosimilars. Here we review the value of public standards as applied to the pharmaceutical industry. Using case studies, we demonstrate how standards for complex products, such as biologics, can be created and managed to ensure their optimal value to society while minimizing the burden to the industry. We also discuss the sustainability of standard development and whether there is sufficient transparency to maintain their role in the public trust. Finally, we assess the ability of standards to promote access to reasonably priced and high-quality biosimilars while enabling efficient product development and review.
Collapse
Affiliation(s)
- Fouad Atouf
- United States Pharmacopeial Convention, Rockville, Maryland 20852.
| | - Jaap Venema
- United States Pharmacopeial Convention, Rockville, Maryland 20852
| |
Collapse
|
20
|
Brinson RG, Arbogast LW, Marino JP, Delaglio F. Best Practices in Utilization of 2D-NMR Spectral Data as the Input for Chemometric Analysis in Biopharmaceutical Applications. J Chem Inf Model 2020; 60:2339-2355. [DOI: 10.1021/acs.jcim.0c00081] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Robert G. Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, The University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - Luke W. Arbogast
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, The University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - John P. Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, The University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| | - Frank Delaglio
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, The University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850, United States
| |
Collapse
|
21
|
Abstract
A proof of concept for new methodology to detect and potentially quantify mAb aggregation is presented. Assay development included using an aggregated mAb as bait for screening of a phage display peptide library and identifying those peptides with random sequence which can recognize mAb aggregates. The selected peptides can be used for developing homogeneous quantitative methods to assess mAb aggregation. Results indicate that a peptide-binding method coupled with fluorescence polarization detection can detect mAb aggregation and potentially monitor the propensity of therapeutic protein candidates to aggregate.
Collapse
|
22
|
De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, Staples GO, Furuki K, Frenkel R, Hu Y, Sosic Z, Zhang P, Altmann F, Grunwald-Grube C, Shao C, Zaia J, Evers W, Pengelley S, Suckau D, Wiechmann A, Resemann A, Jabs W, Beck A, Froehlich JW, Huang C, Li Y, Liu Y, Sun S, Wang Y, Seo Y, An HJ, Reichardt NC, Ruiz JE, Archer-Hartmann S, Azadi P, Bell L, Lakos Z, An Y, Cipollo JF, Pucic-Bakovic M, Štambuk J, Lauc G, Li X, Wang PG, Bock A, Hennig R, Rapp E, Creskey M, Cyr TD, Nakano M, Sugiyama T, Leung PKA, Link-Lenczowski P, Jaworek J, Yang S, Zhang H, Kelly T, Klapoetke S, Cao R, Kim JY, Lee HK, Lee JY, Yoo JS, Kim SR, Suh SK, de Haan N, Falck D, Lageveen-Kammeijer GSM, Wuhrer M, Emery RJ, Kozak RP, Liew LP, Royle L, Urbanowicz PA, Packer NH, Song X, Everest-Dass A, Lattová E, Cajic S, Alagesan K, Kolarich D, Kasali T, Lindo V, Chen Y, Goswami K, Gau B, Amunugama R, Jones R, Stroop CJM, Kato K, Yagi H, Kondo S, Yuen CT, Harazono A, Shi X, Magnelli PE, Kasper BT, Mahal L, Harvey DJ, O'Flaherty R, Rudd PM, Saldova R, Hecht ES, Muddiman DC, Kang J, Bhoskar P, Menard D, Saati A, Merle C, Mast S, Tep S, Truong J, Nishikaze T, Sekiya S, Shafer A, Funaoka S, Toyoda M, de Vreugd P, Caron C, Pradhan P, Tan NC, Mechref Y, Patil S, Rohrer JS, Chakrabarti R, Dadke D, Lahori M, Zou C, Cairo C, Reiz B, Whittal RM, Lebrilla CB, Wu L, Guttman A, Szigeti M, Kremkow BG, Lee KH, Sihlbom C, Adamczyk B, Jin C, Karlsson NG, Örnros J, Larson G, Nilsson J, Meyer B, Wiegandt A, Komatsu E, Perreault H, Bodnar ED, Said N, Francois YN, Leize-Wagner E, Maier S, Zeck A, Heck AJR, Yang Y, Haselberg R, Yu YQ, Alley W, Leone JW, Yuan H, Stein SE. NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods. Mol Cell Proteomics 2020; 19:11-30. [PMID: 31591262 PMCID: PMC6944243 DOI: 10.1074/mcp.ra119.001677] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 08/26/2019] [Indexed: 01/24/2023] Open
Abstract
Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.
Collapse
Affiliation(s)
- Maria Lorna A De Leoz
- Mass Spectrometry Data Center, Biomolecular Measurement Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899.
| | - David L Duewer
- Chemical Sciences Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899
| | - Adam Fung
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Lily Liu
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Hoi Kei Yau
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Oscar Potter
- Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Gregory O Staples
- Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Kenichiro Furuki
- Astellas Pharma, 5-2-3 Tokodai, Tsukiba, Ibaraki, 300-2698, Japan
| | - Ruth Frenkel
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Yunli Hu
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Zoran Sosic
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Peiqing Zhang
- Bioprocessing Technology Institute, 20 Biopolis Way, Level 3 Singapore 138668
| | - Friedrich Altmann
- Department of Chemistry, University of Natural Resources and Life Science, Vienna (BOKU), Muthgasse 18 1190 Wien, Austria
| | - Clemens Grunwald-Grube
- Department of Chemistry, University of Natural Resources and Life Science, Vienna (BOKU), Muthgasse 18 1190 Wien, Austria
| | - Chun Shao
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street Boston, Massachusetts 02118
| | - Joseph Zaia
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street Boston, Massachusetts 02118
| | - Waltraud Evers
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | | | - Detlev Suckau
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Anja Wiechmann
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Anja Resemann
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Wolfgang Jabs
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany; Department of Life Sciences & Technology, Beuth Hochschule für Technik Berlin, Seestraβe 64, 13347 Berlin, Germany
| | - Alain Beck
- Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, BP 60497, 74164 St Julien-en-Genevois, France
| | - John W Froehlich
- Department of Urology, Boston Children's Hospital, 300 Longwood Avenue Boston Massachusetts 02115
| | - Chuncui Huang
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yan Li
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yaming Liu
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Shiwei Sun
- Key Lab of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yaojun Wang
- Key Lab of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Youngsuk Seo
- Graduate School of Analytical Science and Technology, Chungnam National University, Gung-dong 220, Yuseong-Gu, Daejeon 305-764, Korea (South)
| | - Hyun Joo An
- Graduate School of Analytical Science and Technology, Chungnam National University, Gung-dong 220, Yuseong-Gu, Daejeon 305-764, Korea (South)
| | | | | | - Stephanie Archer-Hartmann
- Analytical Services, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road Athens, Georgia 30602
| | - Parastoo Azadi
- Analytical Services, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road Athens, Georgia 30602
| | - Len Bell
- BioCMC Solutions (Large Molecules), Covance Laboratories Limited, Otley Road, Harrogate, North Yorks HG3 1PY, United Kingdom
| | - Zsuzsanna Lakos
- Biochemistry Method Development & Validation, Eurofins Lancaster Laboratories, Inc., 2425 New Holland Pike Lancaster, Pennsylvania 17601
| | - Yanming An
- Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993
| | - John F Cipollo
- Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993
| | - Maja Pucic-Bakovic
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia
| | - Jerko Štambuk
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia
| | - Gordan Lauc
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia; Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, 10 000 Zagreb, Croatia
| | - Xu Li
- Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303
| | - Peng George Wang
- Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303
| | - Andreas Bock
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany
| | - René Hennig
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany
| | - Erdmann Rapp
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany; AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Marybeth Creskey
- Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada
| | - Terry D Cyr
- Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada
| | - Miyako Nakano
- Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | - Taiki Sugiyama
- Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | | | - Paweł Link-Lenczowski
- Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31-126 Krakow, Poland
| | - Jolanta Jaworek
- Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31-126 Krakow, Poland
| | - Shuang Yang
- Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287
| | - Hui Zhang
- Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287
| | - Tim Kelly
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Song Klapoetke
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Rui Cao
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Jin Young Kim
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Hyun Kyoung Lee
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Ju Yeon Lee
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Jong Shin Yoo
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Sa-Rang Kim
- Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363-700, Korea (South)
| | - Soo-Kyung Suh
- Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363-700, Korea (South)
| | - Noortje de Haan
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | - David Falck
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | | | - Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | - Robert J Emery
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Radoslaw P Kozak
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Li Phing Liew
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Louise Royle
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Paulina A Urbanowicz
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Nicolle H Packer
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Xiaomin Song
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Arun Everest-Dass
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Erika Lattová
- Proteomics, Central European Institute for Technology, Masaryk University, Kamenice 5, A26, 625 00 BRNO, Czech Republic
| | - Samanta Cajic
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany
| | - Kathirvel Alagesan
- Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Daniel Kolarich
- Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Toyin Kasali
- AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Viv Lindo
- AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Yuetian Chen
- Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Kudrat Goswami
- Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Brian Gau
- Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103
| | - Ravi Amunugama
- MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108
| | - Richard Jones
- MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108
| | | | - Koichi Kato
- Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, 5-1 Higashiyama, Myodaiji, Okazaki 444-8787 Japan; Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan
| | - Hirokazu Yagi
- Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan
| | - Sachiko Kondo
- Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan; Medical & Biological Laboratories Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464-0858 Japan
| | - C T Yuen
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom
| | - Akira Harazono
- Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501 Japan
| | - Xiaofeng Shi
- New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938
| | - Paula E Magnelli
- New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938
| | - Brian T Kasper
- New York University, 100 Washington Square East New York City, New York 10003
| | - Lara Mahal
- New York University, 100 Washington Square East New York City, New York 10003
| | - David J Harvey
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom
| | - Roisin O'Flaherty
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Pauline M Rudd
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Radka Saldova
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Elizabeth S Hecht
- Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695
| | - David C Muddiman
- Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695
| | - Jichao Kang
- Pantheon, 201 College Road East Princeton, New Jersey 08540
| | | | | | - Andrew Saati
- Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810
| | - Christine Merle
- Proteodynamics, ZI La Varenne 20-22 rue Henri et Gilberte Goudier 63200 RIOM, France
| | - Steven Mast
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Sam Tep
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Jennie Truong
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Takashi Nishikaze
- Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan
| | - Sadanori Sekiya
- Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan
| | - Aaron Shafer
- Children's GMP LLC, St. Jude Children's Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105
| | - Sohei Funaoka
- Sumitomo Bakelite Co., Ltd., 1-5 Muromati 1-Chome, Nishiku, Kobe, 651-2241 Japan
| | - Masaaki Toyoda
- Sumitomo Bakelite Co., Ltd., 1-5 Muromati 1-Chome, Nishiku, Kobe, 651-2241 Japan
| | - Peter de Vreugd
- Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands
| | - Cassie Caron
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Pralima Pradhan
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Niclas Chiang Tan
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Yehia Mechref
- Department of Chemistry and Biochemistry, Texas Tech University, 2500 Broadway, Lubbock, Texas 79409
| | - Sachin Patil
- Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085
| | - Jeffrey S Rohrer
- Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085
| | - Ranjan Chakrabarti
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Disha Dadke
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Mohammedazam Lahori
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Chunxia Zou
- Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Christopher Cairo
- Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Béla Reiz
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Randy M Whittal
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Carlito B Lebrilla
- Department of Chemistry, University of California, One Shields Ave, Davis, California 95616
| | - Lauren Wu
- Department of Chemistry, University of California, One Shields Ave, Davis, California 95616
| | - Andras Guttman
- Horváth Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary
| | - Marton Szigeti
- Horváth Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary
| | - Benjamin G Kremkow
- Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711
| | - Kelvin H Lee
- Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711
| | - Carina Sihlbom
- Proteomics Core Facility, University of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden
| | - Barbara Adamczyk
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Chunsheng Jin
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Niclas G Karlsson
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Jessica Örnros
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Göran Larson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden
| | - Jonas Nilsson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden
| | - Bernd Meyer
- Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany
| | - Alena Wiegandt
- Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany
| | - Emy Komatsu
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2
| | - Helene Perreault
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2
| | - Edward D Bodnar
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Nassur Said
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Yannis-Nicolas Francois
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Emmanuelle Leize-Wagner
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Sandra Maier
- Natural and Medical Sciences Institute, University of Tübingen, Markwiesenstraβe 55, 72770 Reutlingen, Germany
| | - Anne Zeck
- Natural and Medical Sciences Institute, University of Tübingen, Markwiesenstraβe 55, 72770 Reutlingen, Germany
| | - Albert J R Heck
- Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Yang Yang
- Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Rob Haselberg
- Division of Bioanalytical Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| | - Ying Qing Yu
- Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757
| | - William Alley
- Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757
| | | | - Hua Yuan
- Zoetis, 333 Portage St. Kalamazoo, Michigan 49007
| | - Stephen E Stein
- Mass Spectrometry Data Center, Biomolecular Measurement Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899
| |
Collapse
|
23
|
Sheen DA, Shen VK, Brinson RG, Arbogast LW, Marino JP, Delaglio F. Chemometric Outlier Classification of 2D-NMR Spectra to Enable Higher Order Structure Characterization of Protein Therapeutics. CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS : AN INTERNATIONAL JOURNAL SPONSORED BY THE CHEMOMETRICS SOCIETY 2020; 199:10.1016/j.chemolab.2020.103973. [PMID: 34135539 PMCID: PMC8204403 DOI: 10.1016/j.chemolab.2020.103973] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Protein therapeutics are vitally important clinically and commercially, with monoclonal antibody (mAb) therapeutic sales alone accounting for $115 billion in revenue for 2018.[1] In order for these therapeutics to be safe and efficacious, their protein components must maintain their high order structure (HOS), which includes retaining their three-dimensional fold and not forming aggregates. As demonstrated in the recent NISTmAb Interlaboratory nuclear magnetic resonance (NMR) Study[2], NMR spectroscopy is a robust and precise approach to address this HOS measurement need. Using the NISTmAb study data, we benchmark a procedure for automated outlier detection used to identify spectra that are not of sufficient quality for further automated analysis. When applied to a diverse collection of all 252 1H,13C gHSQC spectra from the study, a recursive version of the automated procedure performed comparably to visual analysis, and identified three outlier cases that were missed by the human analyst. In total, this method represents a distinct advance in chemometric detection of outliers due to variation in both measurement and sample.
Collapse
Affiliation(s)
- David A. Sheen
- Chemical Sciences Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
| | - Vincent K. Shen
- Chemical Sciences Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
| | - Robert G. Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850 USA
| | - Luke W. Arbogast
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850 USA
| | - John P. Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850 USA
| | - Frank Delaglio
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, Maryland 20850 USA
| |
Collapse
|
24
|
Lei D, Liu J, Liu H, Cleveland TE, Marino JP, Lei M, Ren G. Single-Molecule 3D Images of "Hole-Hole" IgG1 Homodimers by Individual-Particle Electron Tomography. Sci Rep 2019; 9:8864. [PMID: 31221961 PMCID: PMC6586654 DOI: 10.1038/s41598-019-44978-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 05/30/2019] [Indexed: 12/20/2022] Open
Abstract
The engineering of immunoglobulin-G molecules (IgGs) is of wide interest for improving therapeutics, for example by modulating the activity or multiplexing the specificity of IgGs to recognize more than one antigen. Optimization of engineered IgG requires knowledge of three-dimensional (3D) structure of synthetic IgG. However, due to flexible nature of the molecules, their structural characterization is challenging. Here, we use our reported individual-particle electron tomography (IPET) method with optimized negative-staining (OpNS) for direct 3D reconstruction of individual IgG hole-hole homodimer molecules. The hole-hole homodimer is an undesired variant generated during the production of a bispecific antibody using the knob-into-hole heterodimer technology. A total of 64 IPET 3D density maps at ~15 Å resolutions were reconstructed from 64 individual molecules, revealing 64 unique conformations. In addition to the known Y-shaped conformation, we also observed an unusual X-shaped conformation. The 3D structure of the X-shaped conformation contributes to our understanding of the structural details of the interaction between two heavy chains in the Fc domain. The IPET approach, as an orthogonal technique to characterize the 3D structure of therapeutic antibodies, provides insight into the 3D structural variety and dynamics of heterogeneous IgG molecules.
Collapse
Affiliation(s)
- Dongsheng Lei
- The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA
| | - Jianfang Liu
- The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA
| | - Hongbin Liu
- Protein Analytical Chemistry, Genentech Inc., South San Francisco, CA, 94080, USA
| | - Thomas E Cleveland
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA
| | - John P Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology and the University of Maryland, Rockville, MD, 20850, USA
| | - Ming Lei
- Protein Analytical Chemistry, Genentech Inc., South San Francisco, CA, 94080, USA.
| | - Gang Ren
- The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.
| |
Collapse
|
25
|
Nupur N, Rathore AS. Usability of NISTmAb reference material for biosimilar analytical development. Anal Bioanal Chem 2019; 411:2867-2883. [DOI: 10.1007/s00216-019-01735-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Revised: 02/22/2019] [Accepted: 02/27/2019] [Indexed: 12/17/2022]
|
26
|
Orino K. Binding of Immunoglobulin G to Protoporphyrin IX and Its Derivatives: Evidence the Fab Domain Recognizes the Protoporphyrin Ring. Antibodies (Basel) 2019; 8:E6. [PMID: 31544812 PMCID: PMC6640705 DOI: 10.3390/antib8010006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Revised: 12/19/2018] [Accepted: 12/27/2018] [Indexed: 11/29/2022] Open
Abstract
Immunoglobulin G (IgG) is known to bind zinc via the Fc domain. In this study, biotinylated protoporphyrin IX (PPIX) was incubated with human IgG and then zinc-immobilized Sepharose beads (Zn-beads) were added to the mixture. After washing the beads, the binding of biotinylated PPIX with IgG trapped on Zn-beads was detected using alkaline phosphatase (ALP)-labeled avidin. Human IgG and its Fab domain coated on microtiter plate wells recognized biotin-labeled PPIX and its derivatives, Fe-PPIX and Zn-PPIX, whereas the Fc domain showed some extent of reaction only with Zn-PPIX. When rabbit anti-bovine transferrin (Tf) antibodies were incubated with biotinylated PPIX, the binding of anti-Tf antibodies with apo-Tf was indirectly detected using ALP-labeled avidin, suggesting that even if the antibody is modified with PPIX, the antibody-antigen reaction occurs. These results suggest that the IgG Fab domain recognizes PPIX and its derivatives, probably via the recognition of the PPIX ring. It is unlikely that binding between the Fab domain and PPIX affects the Fc domain-zinc interaction or antigen-antibody reaction.
Collapse
Affiliation(s)
- Koichi Orino
- Laboratory of Veterinary Biochemistry, School of Veterinary Medicine, Kitasato University, Aomori 034-8628, Japan.
| |
Collapse
|
27
|
Brinson RG, Marino JP, Delaglio F, Arbogast LW, Evans RM, Kearsley A, Gingras G, Ghasriani H, Aubin Y, Pierens GK, Jia X, Mobli M, Grant HG, Keizer DW, Schweimer K, Ståhle J, Widmalm G, Zartler ER, Lawrence CW, Reardon PN, Cort JR, Xu P, Ni F, Yanaka S, Kato K, Parnham SR, Tsao D, Blomgren A, Rundlöf T, Trieloff N, Schmieder P, Ross A, Skidmore K, Chen K, Keire D, Freedberg DI, Suter-Stahel T, Wider G, Ilc G, Plavec J, Bradley SA, Baldisseri DM, Sforça ML, Zeri ACDM, Wei JY, Szabo CM, Amezcua CA, Jordan JB, Wikström M. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. MAbs 2018; 11:94-105. [PMID: 30570405 PMCID: PMC6343768 DOI: 10.1080/19420862.2018.1544454] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
The increased interest in using monoclonal antibodies (mAbs) as a platform for biopharmaceuticals has led to the need for new analytical techniques that can precisely assess physicochemical properties of these large and very complex drugs for the purpose of correctly identifying quality attributes (QA). One QA, higher order structure (HOS), is unique to biopharmaceuticals and essential for establishing consistency in biopharmaceutical manufacturing, detecting process-related variations from manufacturing changes and establishing comparability between biologic products. To address this measurement challenge, two-dimensional nuclear magnetic resonance spectroscopy (2D-NMR) methods were introduced that allow for the precise atomic-level comparison of the HOS between two proteins, including mAbs. Here, an inter-laboratory comparison involving 26 industrial, government and academic laboratories worldwide was performed as a benchmark using the NISTmAb, from the National Institute of Standards and Technology (NIST), to facilitate the translation of the 2D-NMR method into routine use for biopharmaceutical product development. Two-dimensional 1H,15N and 1H,13C NMR spectra were acquired with harmonized experimental protocols on the unlabeled Fab domain and a uniformly enriched-15N, 20%-13C-enriched system suitability sample derived from the NISTmAb. Chemometric analyses from over 400 spectral maps acquired on 39 different NMR spectrometers ranging from 500 MHz to 900 MHz demonstrate spectral fingerprints that are fit-for-purpose for the assessment of HOS. The 2D-NMR method is shown to provide the measurement reliability needed to move the technique from an emerging technology to a harmonized, routine measurement that can be generally applied with great confidence to high precision assessments of the HOS of mAb-based biotherapeutics.
Collapse
Affiliation(s)
- Robert G Brinson
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - John P Marino
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Frank Delaglio
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Luke W Arbogast
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Ryan M Evans
- b Applied and Computational Mathematics Division , National Institute of Standards and Technology , Gaithersburg , MD , USA
| | - Anthony Kearsley
- b Applied and Computational Mathematics Division , National Institute of Standards and Technology , Gaithersburg , MD , USA
| | - Geneviève Gingras
- c Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , Ottawa , ON , Canada
| | - Houman Ghasriani
- c Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , Ottawa , ON , Canada
| | - Yves Aubin
- c Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , Ottawa , ON , Canada
| | - Gregory K Pierens
- d The Centre for Advanced Imaging , The University of Queensland , St Lucia , QLD , Australia
| | - Xinying Jia
- d The Centre for Advanced Imaging , The University of Queensland , St Lucia , QLD , Australia
| | - Mehdi Mobli
- d The Centre for Advanced Imaging , The University of Queensland , St Lucia , QLD , Australia
| | - Hamish G Grant
- e Bio21 Molecular Science & Biotechnology Institute , The University of Melbourne , Victoria , Australia
| | - David W Keizer
- e Bio21 Molecular Science & Biotechnology Institute , The University of Melbourne , Victoria , Australia
| | | | - Jonas Ståhle
- g Department of Organic Chemistry , Arrhenius Laboratory, Stockholm University , Stockholm , Sweden
| | - Göran Widmalm
- g Department of Organic Chemistry , Arrhenius Laboratory, Stockholm University , Stockholm , Sweden
| | - Edward R Zartler
- h Analytical R&D , Pfizer Essential Health , Lake Forest , IL , USA
| | - Chad W Lawrence
- i Pacific Northwest National Laboratory , Earth and Biological Sciences Directorate , Richland , DC , USA
| | - Patrick N Reardon
- i Pacific Northwest National Laboratory , Earth and Biological Sciences Directorate , Richland , DC , USA
| | - John R Cort
- i Pacific Northwest National Laboratory , Earth and Biological Sciences Directorate , Richland , DC , USA
| | - Ping Xu
- j Department of Downstream Processing and Analytics , Human Health Therapeutics Research Centre, National Research Council of Canada , Montreal , Quebec , Canada
| | - Feng Ni
- j Department of Downstream Processing and Analytics , Human Health Therapeutics Research Centre, National Research Council of Canada , Montreal , Quebec , Canada
| | - Saeko Yanaka
- k Institute for Molecular Science and Exploratory Research Center on Life and Living Systems , National Institutes of Natural Sciences , Myodaiji, Okazaki , Japan
| | - Koichi Kato
- k Institute for Molecular Science and Exploratory Research Center on Life and Living Systems , National Institutes of Natural Sciences , Myodaiji, Okazaki , Japan
| | - Stuart R Parnham
- l Department of Biochemistry and Molecular Biology , Medical University of South Carolina , Charleston , SC , USA
| | - Desiree Tsao
- m Analytical Development , Momenta Pharmaceuticals , Cambridge , MA , USA
| | - Andreas Blomgren
- n Laboratory Unit , Swedish Medical Products Agency, Laboratory , Uppsala , Sweden
| | - Torgny Rundlöf
- n Laboratory Unit , Swedish Medical Products Agency, Laboratory , Uppsala , Sweden
| | - Nils Trieloff
- o NMR-supported Structural Biology , Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) , Berlin , Germany
| | - Peter Schmieder
- o NMR-supported Structural Biology , Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) , Berlin , Germany
| | - Alfred Ross
- p Roche Pharmaceutical Research & Early Development , Pre-Clinical CMC, Roche Innovation Center Basel , Basel , Switzerland
| | - Ken Skidmore
- q Analytical Operations , Genentech , South San Francisco , CA , USA
| | - Kang Chen
- r Center for Drug Evaluation and Research , Food and Drug Administration , Maryland , USA
| | - David Keire
- r Center for Drug Evaluation and Research , Food and Drug Administration , Maryland , USA
| | - Darón I Freedberg
- s Center for Biologics Evaluation and Research , Food and Drug Administration , Maryland , USA
| | - Thea Suter-Stahel
- t Department of Biology , Institute of Molecular Biology and Biophysics , ETH Zurich, Zurich , Switzerland
| | - Gerhard Wider
- t Department of Biology , Institute of Molecular Biology and Biophysics , ETH Zurich, Zurich , Switzerland
| | - Gregor Ilc
- u NMR Centre , EN-FIST Centre of Excellence , Ljubljana , Slovenia.,v NMR Centre , National Institute of Chemistry , Ljubljana , Slovenia
| | - Janez Plavec
- u NMR Centre , EN-FIST Centre of Excellence , Ljubljana , Slovenia.,v NMR Centre , National Institute of Chemistry , Ljubljana , Slovenia
| | - Scott A Bradley
- w Eli Lilly and Company , Lilly Corporate Center , Indianapolis , IN , USA
| | - Donna M Baldisseri
- x MRS - Application Science , Bruker BioSpin Corporation , Billerica , MA , USA
| | - Mauricio Luis Sforça
- y Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM) , Campinas, Brazil
| | - Ana Carolina de Mattos Zeri
- z Brazilian Synchrotron Light Laboratory (LNLS), Brazilian Center for Research in Energy and Materials (CNPEM) , Campinas, Brazil , CEP
| | - Julie Yu Wei
- aa Protein Product Development , Biogen Inc ., Cambridge , MA , USA
| | - Christina M Szabo
- ab Baxter Pharmaceuticals R&D , Baxter Healthcare , Round Lake, IL , USA
| | - Carlos A Amezcua
- ab Baxter Pharmaceuticals R&D , Baxter Healthcare , Round Lake, IL , USA
| | - John B Jordan
- ac Global Regulatory and R&D Policy , Amgen Inc ., Thousand Oaks , CA , USA
| | - Mats Wikström
- ad Higher Order Structure, Attribute Sciences , Amgen Inc ., Thousand Oaks , CA , USA
| |
Collapse
|
28
|
Reddy PT, Brinson RG, Hoopes JT, McClung C, Ke N, Kashi L, Berkmen M, Kelman Z. Platform development for expression and purification of stable isotope labeled monoclonal antibodies in Escherichia coli. MAbs 2018; 10:992-1002. [PMID: 30060704 PMCID: PMC6204800 DOI: 10.1080/19420862.2018.1496879] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The widespread use of monoclonal antibodies (mAbs) as a platform for therapeutic drug development in the pharmaceutical industry has led to an increased interest in robust experimental approaches for assessment of mAb structure, stability and dynamics. The ability to enrich proteins with stable isotopes is a prerequisite for the in-depth application of many structural and biophysical methods, including nuclear magnetic resonance (NMR), small angle neutron scattering, neutron reflectometry, and quantitative mass spectrometry. While mAbs can typically be produced with very high yields using mammalian cell expression, stable isotope labeling using cell culture is expensive and often impractical. The most common and cost-efficient approach to label proteins is to express proteins in Escherichia coli grown in minimal media; however, such methods for mAbs have not been reported to date. Here we present, for the first time, the expression and purification of a stable isotope labeled mAb from a genetically engineered E. coli strain capable of forming disulfide bonds in its cytoplasm. It is shown using two-dimensional NMR spectral fingerprinting that the unlabeled mAb and the mAb singly or triply labeled with 13C, 15N, 2H are well folded, with only minor structural differences relative to the mammalian cell-produced mAb that are attributed to the lack of glycosylation in the Fc domain. This advancement of an E. coli-based mAb expression platform will facilitate the production of mAbs for in-depth structural characterization, including the high resolution investigation of mechanisms of action.
Collapse
Affiliation(s)
- Prasad T Reddy
- a Biomolecular Labeling Laboratory, Institute for Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Robert G Brinson
- b Institute for Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - J Todd Hoopes
- a Biomolecular Labeling Laboratory, Institute for Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | | | - Na Ke
- c New England Biolabs , Ipswich , MA , USA
| | - Lila Kashi
- a Biomolecular Labeling Laboratory, Institute for Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | | | - Zvi Kelman
- a Biomolecular Labeling Laboratory, Institute for Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| |
Collapse
|
29
|
Kashi L, Yandrofski K, Preston RJ, Arbogast LW, Giddens JP, Marino JP, Schiel JE, Kelman Z. Heterologous recombinant expression of non-originator NISTmAb. MAbs 2018; 10:922-933. [PMID: 29958062 PMCID: PMC6152460 DOI: 10.1080/19420862.2018.1486355] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The successful development and regulatory approval of originator and biosimilar therapeutic proteins requires a systems approach to upstream and downstream processing as well as product characterization and quality control. Innovation in process design and control, product characterization strategies, and data integration represent an ecosystem whose concerted advancement may reduce time-to-market and further improve comparability and biosimilarity programs. The biopharmaceutical community has made great strides to this end, yet there currently exists no pre-competitive monoclonal antibody (mAb) expression platform for open innovation. Here, we describe the development and initial expression of an intended copy of the NISTmAb using three non-originator murine cell lines. It was found that, without optimization and in culture flasks, all three cell lines produce approximately 100 mg mAb per liter of culture. Sodium dodecyl sulfate polyacrylamide gel electrophoresis, size-exclusion chromatography, nuclear magnetic resonance spectroscopy, intact mass spectrometry, and surface plasmon resonance were used to demonstrate that the products of all three cell lines embody quality attributes with a sufficient degree of sameness to the NISTmAb Reference Material 8671 to warrant further bioreactor studies, process improvements and optimization. The implications of the work with regard to pre-competitive innovation to support process design and feedback control, comparability and biosimilarity assessments, and process analytical technologies are discussed.
Collapse
Affiliation(s)
- Lila Kashi
- a Biomolecular Labeling Laboratory , National Institute of Standards and Technology and Institute for Bioscience and Biotechnology Research, University of Maryland , Rockville , MD , USA
| | - Katharina Yandrofski
- b National Institute of Standards and Technology , Institute for Bioscience and Biotechnology Research , Rockville , MD , USA
| | - Renae J Preston
- a Biomolecular Labeling Laboratory , National Institute of Standards and Technology and Institute for Bioscience and Biotechnology Research, University of Maryland , Rockville , MD , USA
| | - Luke W Arbogast
- b National Institute of Standards and Technology , Institute for Bioscience and Biotechnology Research , Rockville , MD , USA
| | - John P Giddens
- b National Institute of Standards and Technology , Institute for Bioscience and Biotechnology Research , Rockville , MD , USA
| | - John P Marino
- b National Institute of Standards and Technology , Institute for Bioscience and Biotechnology Research , Rockville , MD , USA
| | - John E Schiel
- b National Institute of Standards and Technology , Institute for Bioscience and Biotechnology Research , Rockville , MD , USA
| | - Zvi Kelman
- a Biomolecular Labeling Laboratory , National Institute of Standards and Technology and Institute for Bioscience and Biotechnology Research, University of Maryland , Rockville , MD , USA
| |
Collapse
|
30
|
Turner A, Yandrofski K, Telikepalli S, King J, Heckert A, Filliben J, Ripple D, Schiel JE. Development of orthogonal NISTmAb size heterogeneity control methods. Anal Bioanal Chem 2018; 410:2095-2110. [PMID: 29428991 PMCID: PMC5830496 DOI: 10.1007/s00216-017-0819-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 11/03/2017] [Accepted: 12/08/2017] [Indexed: 12/13/2022]
Abstract
The NISTmAb is a monoclonal antibody Reference Material from the National Institute of Standards and Technology; it is a class-representative IgG1κ intended to serve as a pre-competitive platform for harmonization and technology development in the biopharmaceutical industry. The publication series of which this paper is a part describes NIST's overall control strategy to ensure NISTmAb quality and availability over its lifecycle. In this paper, the development of a control strategy for monitoring NISTmAb size heterogeneity is described. Optimization and qualification of size heterogeneity measurement spanning a broad size range are described, including capillary electrophoresis-sodium dodecyl sulfate (CE-SDS), size exclusion chromatography (SEC), dynamic light scattering (DLS), and flow imaging analysis. This paper is intended to provide relevant details of NIST's size heterogeneity control strategy to facilitate implementation of the NISTmAb as a test molecule in the end user's laboratory. Graphical abstract Representative size exclusion chromatogram of the NIST monoclonal antibody (NISTmAb). The NISTmAb is a publicly available research tool intended to facilitate advancement of biopharmaceutical analytics. HMW = high molecular weight (trimer and dimer), LMW = low molecular weight (2 fragment peaks). Peak labeled buffer is void volume of the column from L-histidine background buffer.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/analysis
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal, Humanized/analysis
- Antibodies, Monoclonal, Humanized/chemistry
- Chromatography, Gel/methods
- Chromatography, Gel/standards
- Dynamic Light Scattering/methods
- Dynamic Light Scattering/standards
- Electrophoresis, Capillary/methods
- Electrophoresis, Capillary/standards
- Humans
- Immunoglobulin G/analysis
- Immunoglobulin G/chemistry
- Limit of Detection
- Mice
- Models, Molecular
- Protein Aggregates
- Quality Control
- Reference Standards
- Sodium Dodecyl Sulfate/chemistry
Collapse
Affiliation(s)
- Abigail Turner
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA
- MedImmune, LLC, 55 Watkins Mill Rd, Gaithersburg, MD, 20878, USA
| | - Katharina Yandrofski
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA
| | - Srivalli Telikepalli
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Jason King
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Alan Heckert
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - James Filliben
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Dean Ripple
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - John E Schiel
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA.
| |
Collapse
|
31
|
Mouchahoir T, Schiel JE. Development of an LC-MS/MS peptide mapping protocol for the NISTmAb. Anal Bioanal Chem 2018; 410:2111-2126. [PMID: 29411091 PMCID: PMC5830484 DOI: 10.1007/s00216-018-0848-6] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 12/04/2017] [Accepted: 01/03/2018] [Indexed: 11/12/2022]
Abstract
Peptide mapping is a component of the analytical toolbox used within the biopharmaceutical industry to aid in the identity confirmation of a protein therapeutic and to monitor degradative events such as oxidation or deamidation. These methods offer the advantage of providing site-specific information regarding post-translational and chemical modifications that may arise during production, processing or storage. A number of such variations may also be induced by the sample preparation methods themselves which may confound the ability to accurately evaluate the true modification levels. One important focus when developing a peptide mapping method should therefore be the use of sample preparation conditions that will minimize the degree of artificial modifications induced. Unfortunately, the conditions that are amenable to effective reduction, alkylation and digestion are often the same conditions that promote unwanted modifications. Here we describe the optimization of a tryptic digestion protocol used for peptide mapping of the NISTmAb IgG1κ which addresses the challenge of balancing maximum digestion efficiency with minimum artificial modifications. The parameters on which we focused include buffer concentration, digestion time and temperature, as well as the source and type of trypsin (recombinant vs. pancreatic; bovine vs porcine) used. Using the optimized protocol we generated a peptide map of the NISTmAb which allowed us to confirm its identity at the level of primary structure. Graphical abstract Peptide map of the NISTmAb RM 8671 monoclonal antibody. Tryptic digestion was performed using an optimized protocol and followed by LC-UV-MS analysis. The trace represents the total ion chromatogram. Each peak was mapped to peptides identified using mass spectrometry data.
Collapse
Affiliation(s)
- Trina Mouchahoir
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA.
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD, 20850, USA.
| | - John E Schiel
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
- Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD, 20850, USA
| |
Collapse
|
32
|
Schiel JE, Turner A, Mouchahoir T, Yandrofski K, Telikepalli S, King J, DeRose P, Ripple D, Phinney K. The NISTmAb Reference Material 8671 value assignment, homogeneity, and stability. Anal Bioanal Chem 2018; 410:2127-2139. [PMID: 29411089 PMCID: PMC5830482 DOI: 10.1007/s00216-017-0800-1] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 11/17/2017] [Accepted: 12/04/2017] [Indexed: 12/01/2022]
Abstract
The NISTmAb Reference Material (RM) 8671 is intended to be an industry standard monoclonal antibody for pre-competitive harmonization of best practices and designing next generation characterization technologies for identity, quality, and stability testing. It must therefore embody the quality and characteristics of a typical biopharmaceutical product and be available long-term in a stable format with consistent product quality attributes. A stratified sampling and analysis plan using a series of qualified analytical and biophysical methods is described that assures RM 8671 meets these criteria. Results for the first three lots of RM 8671 highlight the consistency of material attributes with respect to size, charge, and identity. RM 8671 was verified to be homogeneous both within and between vialing lots, demonstrating the robustness of the lifecycle management plan. It was analyzed in concert with the in-house primary sample 8670 (PS 8670) to provide a historical link to this seminal material. RM 8671 was verified to be fit for its intended purpose as a technology innovation tool, external system suitability control, and cross-industry harmonization platform. Graphical abstract The NISTmAb Reference Material (RM) 8671 is intended to be an industry standard monoclonal antibody for pre-competitive harmonization of best practices and designing next generation characterization technologies for identity, quality, and stability testing.
Collapse
Affiliation(s)
- John E Schiel
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA.
| | - Abby Turner
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA
- , 55 Watkins Mill Rd., Gaithersburg, MD, USA
| | - Trina Mouchahoir
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA
| | - Katharina Yandrofski
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA
| | - Srivalli Telikepalli
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Jason King
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Paul DeRose
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Dean Ripple
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| | - Karen Phinney
- National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA
| |
Collapse
|
33
|
Turner A, Schiel JE. Qualification of NISTmAb charge heterogeneity control assays. Anal Bioanal Chem 2018; 410:2079-2093. [PMID: 29423598 PMCID: PMC5830499 DOI: 10.1007/s00216-017-0816-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 11/22/2017] [Accepted: 12/07/2017] [Indexed: 01/21/2023]
Abstract
The NISTmAb is a monoclonal antibody Reference Material from the National Institute of Standards and Technology; it is a class-representative IgG1κ intended serve as a pre-competitive platform for harmonization and technology development in the biopharmaceutical industry. The publication series of which this paper is a part describes NIST's overall control strategy to ensure NISTmAb quality and availability over its lifecycle. In this paper, the development and qualification of methods for monitoring NISTmAb charge heterogeneity are described. Capillary zone electrophoresis (CZE) and capillary isoelectric focusing (CIEF) assays were optimized and evaluated as candidate assays for NISTmAb quality control. CIEF was found to be suitable as a structural characterization assay yielding information on the apparent pI of the NISTmAb. CZE was found to be better suited for routine monitoring of NISTmAb charge heterogeneity and was qualified for this purpose. This paper is intended to provide relevant details of NIST's charge heterogeneity control strategy to facilitate implementation of the NISTmAb as a test molecule in the end user's laboratory. Graphical Abstract Representative capillary zone electropherogram of the NIST monoclonal antibody (NISTmAb). The NISTmAb is a publicly available research tool intended to facilitate advancement of biopharmaceutical analytics.
Collapse
Affiliation(s)
- Abigail Turner
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA
- Medimmune, LLC, 55 Watkins Mill Rd, Gaithersburg, MD, 20878, USA
| | - John E Schiel
- National Institute of Standards and Technology, Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, MD, 20850, USA.
| |
Collapse
|